FDG PET/CT and Directed Metabolic Core Needle Biopsy in the Management of Lymphoma

Post Graduate Institute of Medical Education and Research, Chandigarh

Status: Completed

Conditions: Lymphoma

Treatments: Procedure: FDG PET/CT guided metabolic core needle biopsy

Study type: Observational

Funder types: Other

Identifiers

NCT05186610

NK/1702/MD/11449-50

Details and patient eligibility

About

FDG-PET/CT is an established modality in various stages of management of lymphoma but definitive information regarding the diagnosis, prognostication, and further management is provided by histopathological examination. Combining the two modalities may provide an incremental benefit by identifying better sites for targetting biopsy and for better verification of sites and causes of FDG uptake seen during PET/CT.

Full description

Written informed consent was obtained from all the participants for PET/CT-guided biopsy. The procedure details, related risks, and benefits were explained to all the participants. A multidisciplinary team including hemato-oncologists, nuclear medicine physicians, and pathologists were involved in the project. A hemato-oncologist decided the biopsy indication after discussing it with the nuclear medicine physician. FDG avid lesions in a clinically suspected case of lymphoma or a suspicious, residual FDG avid lesion detected at the time of follow-up PET/CT imaging in a patient with a prior diagnosis of lymphoma were sampled. The per and post-procedural complications and management were maintained in the institutional PET data registry and the final histopathological diagnosis obtained was also collected.

Enrollment: 480 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• FDG avid lesion in a clinically suspected case of lymphoma.
• Suspicious, residual FDG avid lesion detected at the time of follow-up PET/CT imaging in a patient with a prior diagnosis of lymphoma either at the end-of-treatment or during surveillance.

Exclusion criteria

• Deranged coagulation profile.
• Inaccessibility of the lesion for a percutaneous biopsy.
• Resolution of the lesion at the time of biopsy planning.
• Participant is not willing for the procedure.
• Pregnant females and participants less than 18 years of age.

Trial design

480 participants in 1 patient group

FDG PET/CT guided metabolic core needle biopsy group

Description:

2- Fluorodeoxyglucose (FDG) PET-positive lesions at initial presentation or at the end of treatment were considered for PET/CT guided biopsy after discussion with the hemato oncologist.

Treatment:

Procedure: FDG PET/CT guided metabolic core needle biopsy